Otros idiomas Optimi Health Corp.

Acciones

OPTI

CA68405H1001

Diferido Canadian Securities Exchange Otros sitios de cotización 17:17:51 22/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,375 ^CAD	0,00 %		+5,63 %	+53,06 %

14/05	Optimi Health Recibe el Certificado de Análisis para las Cápsulas de Mdma 40Mg y 60Mg Gmp	CI
23/04	Optimi Health y el Centro de Genómica Aplicada de la Universidad Politécnica de Kwantlen se asocian para avanzar en la ciencia y la investigación de los hongos	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial	15:42
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder	14:32
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder	14:31
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules	14/05
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules	14/05
Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	14/05
Optimi Health Provides Corporate Update	10/05
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research	09/05
Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research	09/05
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research	23/04
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research	23/04
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)	15/04
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)	15/04
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	15/04
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute	09/04
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	09/04
Early Warning Press Release in Accordance with National Instrument 62-103	04/04
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract	02/04
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract	02/04
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference	28/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Optimi Health Corp.

Acciones

OPTI

CA68405H1001

Otros idiomas

Filtros